nejm semaglutide ckd The FLOW trial: #semaglutide significantly reduces the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and chronic kidney disease. #CKD @NEJM https://t.co/raVb2h96Pp Updates in Medicine | 🩺

These deliver the essential amino acids your body needs while minimising discomfort

One of the reasons I focus one hundred percent of my efforts on longevity biotechnology is to give people the freedom to enjoy a few more (and potentially many more) years of productive life

February 10, 2023

Dual Incretin Research Peptide Mechanism of Action Preclinical studies have examined this dual incretin research peptide across two primary receptor pathways: GLP-1 Receptor (GLP-1R) Activation Glucose-dependent insulinotropic signaling and beta-cell functional studies Gastric emptying rate modulation in metabolic models Hypothalamic appetite-regulatory pathway research Incretin hormone signaling cascade studies GIP Receptor (GIPR) Activation Nutrient-responsive insulin secretion pathway research Adipocyte signaling and lipid metabolism studies Post-prandial glucose handling models Synergistic incretin co-activation research The combined GLP-1R/GIPR agonism profile referred to in research literature as twincretin activity enables investigation of bimodal incretin signaling